388 results on '"Zuily, Stéphane"'
Search Results
2. Impact of thrombophilia on venous thromboembolism management
3. Epidemiology, natural history, diagnosis, and management of ovarian vein thrombosis: a scoping review
4. Manual versus automatic chest compression devices for cardiopulmonary resuscitation under zero gravity (The MACCC - 0G STUDY)
5. Venous recanalisation in the setting of post-thrombotic syndrome: An expert consensus from the French Society of Vascular Medicine (SFMV) and the French Society of Cardiovascular Imaging and Interventional Radiology (SFICV)
6. Toward harmonized interpretation of anticardiolipin and anti–β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
7. A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
8. Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and/or antiaggregation always required?
9. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
10. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
11. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study
12. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis
13. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
14. Manual rotation of occiput posterior or transverse positions: a systematic review and meta-analysis of randomized controlled trials
15. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
16. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis
17. Thromboprophylaxis strategies to improve the prognosis of COVID-19
18. Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence
19. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
20. Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome
21. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials
22. Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration
23. Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study
24. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis
25. Membranous nephropathy in primary antiphospholipid syndrome
26. CT angiography and MRI of hand vascular lesions: technical considerations and spectrum of imaging findings
27. Expanding the genetic and clinical spectrum of Tatton- Brown- Rahman syndrome in a series of 24 French patients.
28. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis
29. Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin
30. Tocilizumab and refractory Takayasu disease: Four case reports and systematic review
31. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report
32. Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests
33. Disease and Risk Measurement Criteria in Antiphospholipid Syndrome
34. Definition and Epidemiology of Antiphospholipid Syndrome
35. New 2023 classification criteria for antiphospholipid syndrome (ACR/EULAR 2023)
36. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus
37. Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis
38. New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis
39. Health-Related Quality of Life in Antiphospholipid Syndrome: Current Knowledge and Future Perspectives
40. CHAPITRE 1 - Acrosyndromes
41. Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?
42. Editorial: Advances in thrombin generation
43. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis
44. Le syndrome des antiphospholipides en néphrologie. Atteinte rénale et aspects pratiques de la prise en charge
45. Brief Report on the 11th Meeting of the European Forum on Antiphospholipid Antibodies
46. Les nouveaux critères de classification 2023 du syndrome des antiphospholipides (critères ACR/EULAR 2023) *.
47. Les nouveaux critères de classification 2023 du syndrome des antiphospholipides (critères ACR/EULAR 2023) *.
48. Brief Report on the 10th Meeting of the European Forum on Antiphospholipid Antibodies
49. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature
50. Neural Network Diagnoses the Antiphospholipid Syndrome without Interrupting Anticoagulant Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.